menu
    • menu

    Company profile for Response Pharmaceuticals

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Response Pharmaceuticals, Inc, is a clinical-stage therapeutic development company focused on developing treatments for weight management and metabolic disease. Its initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments. Response is developing RDX-002 as an adjunctive therapy for patients taking ...
    Response Pharmaceuticals, Inc, is a clinical-stage therapeutic development company focused on developing treatments for weight management and metabolic disease. Its initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments. Response is developing RDX-002 as an adjunctive therapy for patients taking first-line antipsychotic therapy. RDX-002 is a first-in-class potent and selective inhibitor of intestinal MTP.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Response PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1104 West Broad Street #1064 Falls Church, VA 22046
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.responsepharmaceuticals.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data
    Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data

    05 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260305303028/en/Response-Pharmaceuticals-Reports-Positive-36-Week-Phase-2-Data-Supporting-RDX-002-as-a-Long-Term-Option-in-Post-GLP-1-Receptor-Agonist-Weight-Management

    BUSINESSWIRE
    05 Mar 2026
    Share Share
    Response’s Ex-Sanofi Asset Hits Goal in Post-GLP-1 Patients
    Response’s Ex-Sanofi Asset Hits Goal in Post-GLP-1 Patients

    15 Aug 2025

    // FIECE BIOTECH

    https://www.fiercebiotech.com/biotech/responses-ex-sanofi-asset-hits-midphase-goal-post-glp-1-patients

    FIECE BIOTECH
    15 Aug 2025
    Share Share
    Response Pharma Completes Enrollment of Phase 2 Study for RDX-002
    Response Pharma Completes Enrollment of Phase 2 Study for RDX-002

    06 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250206443806/en

    BUSINESSWIRE
    06 Feb 2025
    Share Share
    Response Pharma Enrolls 1st Patients In Ph 2, Evaluating RDX-002
    Response Pharma Enrolls 1st Patients In Ph 2, Evaluating RDX-002

    17 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241016786749/en

    BUSINESSWIRE
    17 Oct 2024
    Share Share
    Response Pharma AIWG Drug Meets Phase 1b Endpoint
    Response Pharma AIWG Drug Meets Phase 1b Endpoint

    23 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240423868454/en

    BUSINESSWIRE
    23 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search